Published in Pediatr Blood Cancer on June 01, 2008
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111
The adolescent and young adult with cancer: state of the art-- acute leukemias. Curr Oncol Rep (2013) 0.86
Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia (2008) 0.84
Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report. Exp Hematol Oncol (2012) 0.79
Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study. Curr Oncol (2013) 0.79
Acute Pancreatitis and Diabetic Ketoacidosis following L-Asparaginase/Prednisone Therapy in Acute Lymphoblastic Leukemia. Case Rep Oncol Med (2014) 0.79
Prevalence of transient hyperglycemia and diabetes mellitus in pediatric patients with acute leukemia. Iran J Ped Hematol Oncol (2014) 0.77
Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia. PLoS One (2015) 0.75
L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha. Indian J Pharmacol (2016) 0.75
Transient hyperglycaemia - an underestimated problem of paediatric oncohaematology. Arch Med Sci (2012) 0.75
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
The tumor lysis syndrome. N Engl J Med (2011) 4.29
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol (2008) 2.49
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet (2009) 2.37
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol (2008) 2.14
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
Neoplastic causes of abnormal puberty. Pediatr Blood Cancer (2013) 2.12
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet (2003) 2.00
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94
Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA (2002) 1.93
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 1.93
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol (2013) 1.88
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2006) 1.82
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst (2013) 1.81
Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc (2013) 1.80
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet (2003) 1.79
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79
New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78
Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol (2013) 1.76
Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol (2003) 1.75
Childhood cancer epidemiology in low-income countries. Cancer (2008) 1.74
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood (2002) 1.74
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer (2010) 1.69
Changes in outcomes (1996-2004) for pediatric oncology and hematopoietic stem cell transplant patients requiring invasive mechanical ventilation. Pediatr Crit Care Med (2008) 1.68
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66
Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer (2006) 1.64
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62
Impact of an education program on late diagnosis of retinoblastoma in Honduras. Pediatr Blood Cancer (2007) 1.62
Saving the children--improving childhood cancer treatment in developing countries. N Engl J Med (2005) 1.62
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60
Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer (2011) 1.59
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell (2005) 1.58
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA (2004) 1.56
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 1.56
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.53
Feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr Phys Ther (2014) 1.53
Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood (2006) 1.52
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood (2003) 1.51
Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 1.49
Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis (2011) 1.49
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet (2014) 1.49
Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol (2005) 1.48
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma (2003) 1.48
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol (2004) 1.48
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood (2010) 1.47
Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer (2007) 1.47
Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer (2008) 1.46
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest (2005) 1.46
Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma (2009) 1.45